IGM Biosciences, Inc.·4

Aug 14, 5:24 PM ET

Strohl William 4

4 · IGM Biosciences, Inc. · Filed Aug 14, 2025

Insider Transaction Report

Form 4
Period: 2025-08-14
Transactions
  • Disposition to Issuer

    Common Stock

    2025-08-14125,0000 total
Footnotes (1)
  • [F1]Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.

Documents

1 file
  • 4
    form4-08142025_090837.xmlPrimary